Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02556632 · ClinicalTrials.gov registry record · Phase 2
Prophylactic Topical Agents in Reducing Radiation-Induced Dermatitis in Patients With Non-inflammatory Breast Cancer
A Phase 2 study, sponsored by Gary Morrow.
- Completed
- Registry status
- Phase 2
- Development phase
- 191
- Enrollment target
NCT02556632: Completed Phase 2 study, sponsored by Gary Morrow.
NCT02556632 is a Phase 2 study that has completed, run by Gary Morrow. The registered enrollment target is 191 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (44% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02556632, a Phase 2 study, has completed, sponsored by Gary Morrow.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 191 participants
- Enrollment target
Study Summary
This randomized pilot phase II trial studies and compares prophylactic topical agents in reducing radiation-induced dermatitis in patients with non-inflammatory breast cancer or breast cancer in situ. The prophylactic topical agents, such as curcumin-based gel or HPR Plus, may reduce the severity of the radiation-induced dermatitis by minimizing water loss and inflammation during radiation therapy.
Primary Outcome
The mean 1 week post-RT RDS score for each arm will be compared using ANOVA to determine if the topical interventions reduce the severity of skin reactions at the end of RT. The RDS score ranges from 0-4 with higher scores indicating worse outcome.
Interventions
- OTHER Placebo
- OTHER Laboratory Biomarker Analysis
- OTHER Questionnaire Administration
- DRUG Curcumin-based Gel
- PROCEDURE Dermatologic Complications Management
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 191 participants |
| Start Date | 2015-10-13 |
| Est. Completion | 2016-09-30 |
| Phase | Phase 2 |
What the finished NCT02556632 record still lists
NCT02556632 is an interventional study that assigns participants to a tested intervention. The registered 191 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (44% higher).
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT02556632 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02556632 about?
NCT02556632 is a clinical study titled "Prophylactic Topical Agents in Reducing Radiation-Induced Dermatitis in Patients With Non-inflammatory Breast Cancer". This randomized pilot phase II trial studies and compares prophylactic topical agents in reducing radiation-induced dermatitis in patients with non-inflammatory breast cancer or breast cancer in situ. The prophylactic topical agents, such as curcumin-based gel or HPR Plus, may reduce the severity of...
What is the current status of trial NCT02556632?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 191 participants. The study started on 2015-10-13. Estimated completion is 2016-09-30.
What interventions are being tested in trial NCT02556632?
The interventions under investigation include: Placebo (OTHER), Laboratory Biomarker Analysis (OTHER), Questionnaire Administration (OTHER), Curcumin-based Gel (DRUG), Dermatologic Complications Management (PROCEDURE).
Who is sponsoring clinical trial NCT02556632?
This trial is sponsored by Gary Morrow, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02556632's enrollment target sits among peer trials
191 353rd of 2000 higher than 1,648 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04621435 · 191 participants · Phase 1
Imaging of Solid Tumors Using FAP-2286
- NCT06810544 · 191 participants · Phase 1
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
- NCT01492972 · 192 participants · Phase 3
Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer
- NCT01973881 · 192 participants
Quantitative MRI for Myelofibrosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI